This report was first published by Endpoints News. To see the original version, click here
CMS has launched a new drug payment pilot model for state Medicaid programs, the first of potentially multiple pricing models that the pharma industry has been closely monitoring.
The Center for Medicare and Medicaid Innovation (CMMI) unveiled the GENEROUS model Thursday afternoon, a voluntary program that state medicaid programs can opt into. As described, programs that participate will be able to purchase drugs in the pilot program at prices similar to fellow wealthy nations, a nod at the most favored nation push that President Donald Trump has pushed for.